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Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western 
World. In approximately 70% of newly diagnosed cases, CLL presents at an early clinical stage 
and is managed with a watch & wait strategy. Until now, few clinical and molecular predictors 
inform on the risk of treatment requirement. On these grounds, we aimed at identifying new 
molecular markers that may predict early treatment requirement and may help clinicians to 
better plan the watch & wait strategy in asymptomatic early stage CLL patients. 295 Binet A 
CLL patients who referred to our institution were subjected to next-generation-sequencing 
(NGS) in a panel of recurrently mutated genes in CLL. Two validation multicenter cohorts of 
402 treatment-naïve Binet A CLL patients (Binet A validation cohort) and 395 untreated Rai 0 
CLL patients (Rai 0 validation cohort) were also included and analyzed for XPO1 mutations. 
The primary endpoint was time to first treatment (TTFT). In the training cohort, NGS 
mutational analysis showed that XPO1 was mutated in 7 (2.4%) patients. In univariate analysis, 
trisomy 12 (HR 2.42; 95% CI 1.43-4.15; p=0.001), unmutated IGHV genes (HR 4.51; 95% CI 
2.83-7.05; p<0.0001) and mutations of XPO1 (HR 8.88; 95% CI 3.77-20.95; p<0.0001), 
NOTCH1 (HR 3.02; 95% CI 1.66-5.51; p<0.001) and SF3B1 (HR 2.65; 95% CI 1.15-6.10; 
p=0.022) were associated with a shorter TTFT. By multivariate analysis, XPO1 mutations (HR 
4.24; 95% CI 1.72-10.44; p=0.002) and unmutated IGHV genes (HR 3.43; 95% CI 2.08-5.67; 
p<0.0001) maintained an independent association with a shorter TTFT. XPO1 mutational 
analysis was subsequently investigated in 2 independent multicenter cohorts of early stage CLL 
patients. In the Binet A validation cohort (N=402 patients), XPO1 was mutated in 15 (3.7%) 
patients and was associated with a shorter TTFT (HR 2.59; 95% CI 1.36-4.96; p=0.004). 
Similarly, also in the Rai 0 validation cohort, (N=395 patients), XPO1 was mutated in 8 (2.0%) 
patients and was associated with a shorter TTFT (HR 6.02; 95% CI 15.03-4.96; p<0.001). By 
combining the training and the validation cohorts (N=1092 patients), a total of 30 somatically 
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acquired XPO1 mutations were identified (2.7% of patients). More precisely, 27 (90.0%) 
mutations affected XPO1 codon E571 and 3 (10.0%) codon D624. From a clinical perspective, 
patients carrying either XPO1 E571 or D624 mutations showed superimposable outcome in 
terms of TTFT (p=0.345). Based on these results, XPO1 mutational analysis might be 
incorporated in other prognostic scores and help clinicians to refine the management of the 




1.1 Definition and epidemiology 
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western 
World, with an approximate incidence rate of roughly 4.5 new cases per 100,000 individuals 
annually and a median age at diagnosis of 72 years old (Hallek et al., 2008). Males are affected 
by CLL more than females with a male to female ratio of 1.5-2 (Howlader et al., 2016). CLL is 
characterized by the clonal proliferation and accumulation of mature B cells within the 
peripheral blood (PB), bone marrow and other lymphatic tissues.   
The diagnosis of CLL requires the presence of > 5x109/L clonal B lymphocytes in 
peripheral blood during at least 3 months. Some morphological traits of CLL can be observed 
in a blood smear: small, mature lymphocytes, a narrow border of cytoplasm, a dense nucleus 
without dissemble nucleoli and partially aggregated chromatin and Gumprecht nuclear 
shadows (Hallek et al., 2018). CLL cells express the B cells antigens: CD19, CD20, CD23 and 
T-cell surface antigen CD5. The levels of surface immunoglobulin, CD20 and CD79b are low 
compared with a normal B cell. In those borderline cases, other markers like CD43, CD81, 
CD200, CD10 and ROR1 can support the diagnosis (Hallek et al., 2008; Cheson et al., 1996).  
CLL is an indolent neoplasia, with a median survival of 12-15 years and requires 
treatment only in cases of symptomatic disease. Most patients affected by CLL are 
asymptomatic at diagnosis, while some patients may present systemic B-cell symptoms, 
lymphadenopathy, hepatosplenomegaly, bone marrow (BM) infiltration, that indicate 
treatment requirement (Hallek et al., 2018). Active disease should be clearly documented to 
initiate therapy. At least 1 of the following criteria should be met: i) evidence of progressive 
marrow failure as manifested by the development of, or worsening of, anemia and/or 
thrombocytopenia; ii) massive (ie, ≥6 cm below the left costal margin) or progressive or 
symptomatic splenomegaly; iii) bulky lymph nodes (ie, ≥10 cm in longest diameter) or 
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progressive or symptomatic lymphadenopathy; iv) progressive lymphocytosis with an increase 
of ≥50% over a 2-month period, or lymphocyte doubling time (LDT) <6 months; v) 
autoimmune complications including anemia or thrombocytopenia poorly responsive to 
corticosteroids;  vi) symptomatic or functional extranodal involvement; vii) disease-related 
symptoms such a unintentional weight loss, significant fatigue, fever without evidence of 
infection and night sweats for ≥1 month without evidence of infection. 
  
1.2 Clinical markers in asymptomatic CLL patients            
The first prognostic marker used in the clinical management of CLL was the Rai clinical 
staging system, published in 1975 (Rai et al., 1975). The system includes lymphadenopathy, 
organomegaly, and cytopenia (anemia and thrombocytopenia) to establish five prognostic 
groups that can be used to predict median survival of newly diagnosed CLL patients. Patients 
with stage 0 have a median survival of >150 months, with stage I of 101 months, with stage II 
of 71 months and with stages III or IV of 19 months.  
Similarly, a subsequent staging system, namely Binet staging system, was published in 
1981. In this score, CLL patients are classified by the number of affected superficial lymphoid 
tissue regions (cervical lymph nodes, axillary lymph nodes and inguinal lymph nodes), spleen, 
and liver and by the presence or not of anemia or thrombocytopenia. Binet A patients are 
characterized by the involvement of less than 3 lymphoid areas and by the absence of anemia 
or thrombocytopenia. Binet B patients have three or more involved lymphoid areas without 
anemia or thrombocytopenia. Binet C patients present with anemia and/or thrombocytopenia 
regardless of the number of involved lymphoid areas (Binet et al., 1981). In approximately 
70% of newly diagnosed cases, CLL presents at an early clinical stage, namely Binet A, and is 
managed with a watch & wait strategy.  
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1.3 Prognostic markers in asymptomatic CLL patients  
The clinical course of CLL ranges from a very indolent condition, with a nearly normal 
life expectancy, to rapidly progressive leading to early death (Raponi et al., 2018; Rossi et al., 
2015). The majority of CLL patients do not need treatment at the time of diagnosis, but they 
require treatment during their lifetime. This clinical observation is very helpful to identify 
markers at the time of diagnosis, that may be able to predict the course of the disease. 
Prognostic biomarkers provide useful information about the biology and the natural history of 
CLL in the absence and/or independent of the treatment received (Dearden et al., 2008). 
In the past decade, a large body of genomic investigations have deciphered the genome 
of CLL. Elucidation of the CLL genomic landscape has substantiated the notion that CLL is 
not associated with a unique genetic lesion but, conversely, that this leukemia harbors many 
different genetic abnormalities that may interact and/or surrogate and complement in inducing 
the development and progression of CLL. Until now, few clinical and molecular predictors 
inform on the risk of treatment requirement and the impact of CLL gene mutations is not 
completely understood (Gaidano et al., 2017). 
             The pattern of tumor growth of untreated CLL has been investigated by analyzing 
serial longitudinal samples collected between diagnosis and the time of treatment requirement. 
Two different patterns of growth have been identified. The exponential growth pattern is 
characterized by a rapid proliferation of the CLL clone, whereas the logistic growth pattern 
displays a lower rate of progression. These two different patterns of growth associate with 
peculiar molecular features. CLL cases with an exponential growth are mainly immunoglobulin 
heavy variable (IGHV) unmutated CLL and have a higher frequency of clonal and subclonal 
somatic genetic lesions compared to patients with a logistic growth pattern. These different 
growth patterns, as well as the association between exponential growth, unmutated IGHV 
genes, and additional genetic lesions, have been validated in an independent cohort of CLL 
 8 
patients (Gruber et al., 2019). 
Other studies have focused on the identification of clinical and molecular features that 
might identify early stage CLL who are at risk of early progression at the time of diagnosis. 
Such patients, if identified a priori, might benefit from clinical trials comparing early 
intervention versus observation. In this context, the combination of simple clinical features and 
molecular biomarkers, namely lymphocyte count >15,000/L, palpable lymph nodes, and 
unmutated IGHV genes, identifies three different subgroups of Binet A and treatment naïve 
CLL patients with a high risk of early treatment requirement (Condoluci et al., 2020). This risk 
model, termed IPS-E (International Prognostic Score-Early), has been validated in several 
independent series and is a robust tool to inform at the time of diagnosis about the probability 
that a given CLL patient in early stage disease progresses and needs treatment (Condoluci et 
al., 2020). Similarly, the second model for Rai 0 CLL identified 17p deletion, 11q deletion, 
trisomy 12, unmutated and white blood cell count above 32,000/L as variable associated with 
shorter TTFT.7 These models do not take into account the clinical impact of gene mutations 
that may allow a more precise stratification of early stage CLL patients (Cohen et al., 2020). 
            In addition, by taking advantage of the genetic heterogeneity of CLL, mutations of 
genes involved in CLL pathogenesis have been tested as biomarkers for identifying early stage 
CLL patients with a higher risk of progression and treatment requirement. These studies point 
to mutations of SF3B1, NOTCH1, ATM, and U1 as molecular predictors of shorter time to first 
treatment (TTFT) (Shuai et al., 2019; Hu et al. 2019; Moia et al., 2019). 
              Interestingly, TP53 disruption is not associated with a shorter TTFT, in line with the 
notion that TP53 disruption interacts with treatment with chemotherapeutic agents, but not with 
a watch and wait strategy that does not expose CLL cells carrying TP53 disruption to the 
positive selection pressure exerted by ineffective chemotherapy. The precise role of gene 
mutations in sorting asymptomatic CLL patients with an imminent risk of treatment 
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requirement still needs to be clarified and is the current subject of investigations. (Hu et al., 
2019; Condoluci et al., 2020). 
  
1.4 Management of asymptomatic CLL patients 
 Approximately 70% of newly diagnosed CLL patients presents in an early stage 
according to the Binet and Rai staging systems, may never require treatment, and may have a 
life expectancy similar to the general population (Halek et al., 2018; Binet et al., 1981; Rai et 
al., 1975). Asymptomatic early stage CLL patients, till now, are managed with a watch and 
wait strategy, and treatment is started only in case of symptomatic disease including 
progressive lymphocytosis, enlarged lymph nodes, cytopenia, and systemic symptoms (Hallek 
et al., 2018). Three clinical trials comparing chlorambucil, fludarabine and fludarabine, 
cyclophosphamide and rituximab (FCR) versus placebo in high risk asymptomatic CLL 
patients did not prolong survival in early stage asymptomatic CLL patients (Dighiero et al., 
1998; Hoechstetter et al., 2017; Herling et al., 2020; Langerbeins et al., 2019). The three above 
mentioned clinical trials compared chemoimmunotherapy (CIT) versus observation, whereas, 
recently, the phase 3 CLL12 clinical trial compared ibrutinib versus observation in 
asymptomatic CLL patients. Preliminary results have demonstrated a higher progression free 
survival (PFS) rate in the ibrutinib arm, compared to placebo. However, survival data are not 
mature enough to demonstrate a clearly advantage of ibrutinib versus observation (Langerbeins 
et al., 2019). Therefore, guidelines still recommend a watch and wait strategy for asymptomatic 
CLL patients (Hallek et al., 2019). 
 
1.5 The XPO1 gene 
Exportin-1 (XPO1), also called chromosome region maintenance 1 (CRM1), is a pivotal 
eukaryotic nuclear export protein that carries an extensive array of proteins from the nucleus 
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to the cytoplasm. XPO1 is a member of the importin-β superfamily of karyopherins that 
mediates the translocation of numerous RNAs and cellular regulatory proteins, including tumor 
suppressor proteins (TSPs). Thanks to the energy given by RanGTP, XPO1 can export out of 
the nucleus some cargo proteins. The cargo proteins of XPO1 include TP53, RB, p21 and other 
anti-apoptotic proteins. In the cytoplasm, the complex dissociates and XPO1 goes back to the 
nucleus to repeat its biological activity (Figure 1). XPO1 is overactive in many cancers, and 
thus has been considered a potential anti-cancer target for decades (Huang et al., 2009). XPO1 
is a therapeutic target and selective inhibitors of nuclear transport (SINE) such as selinexor are 
now being investigated in clinical trials in CLL and in other lymphoid malignancies 
(Lapalombella et al., 2012).  
Furthermore, recent studies have focused on the characterization of the molecular 
alterations in the XPO1 gene. In primary mediastinal diffuse large B cell lymphoma (PMBL) 
and classical Hodgkin’s lymphoma (cHL) a mutational hotspot affecting the codon E571K 
(Jardin et al., 2016) has been identified. Missense substitutions targeting XPO1 have also been 
previously reported also in other hematological and non-hematological malignancies (Jeromin 
et al., 2014). Pre-clinical models showed that XPO1 mutations, and in particular the E571K 
hotspot, seems to enhance the affinity of XPO1 to the cargo proteins that are exported out of 
the nucleus with a greater extent. In this way, the nucleus is deprived of antiapoptotic proteins 
that may lead to an uncontrolled cell proliferation. Regarding prognosis, high levels of XPO1 
are associated with shorter survival and are a poor prognostic factor in acute myeloid leukemia 
and in other solid cancers (Kojima et al., 2013 Azmi et al., 2020).  
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Figure 1: The XPO1 pathway. The XPO1 protein exports nuclear proteins (cargo) from the nucleus to the 
cytoplasm thanks to the energy provided by the RanGTP. The complex of XPO1, RanGTP and the cargo protein 
is disassembled in the cytoplasm, cargo is released, and XPO1 is recycled back to the nucleus. XPO1 mutations 




































2 AIM OF THE THESIS 
 CLL is a highly heterogeneous disease; some patients may never require treatment, 
whereas other relapse early after frontline therapy. In approximately 70% of newly diagnosed 
cases, CLL present at an early clinical stage and is managed with a watch & wait strategy. The 
IPS-E and the Rai 0 prognostic score identify patients with early treatment requirement but the 
impact of CLL gene mutations is not completely understood.  
Consistently, the aim of this thesis was to identify new molecular markers that may 
predict early treatment requirement and may help clinicians to better plan the watch & wait 


















3 MATERIALS AND METHODS 
3.1 Patients   
           This training cohort included a cohort of 295 Binet A CLL patients. The following 
biological material was collected: i) 295 tumor genomic DNA (gDNA) from PB 
mononuclear cells at the time of diagnosis; ii) paired germline DNA from saliva for 56 cases; 
and iii) normal gDNA from 6 healthy donors was also used to set the experimental and 
biological background of the deep next generation sequencing (NGS) approach. Patients 
provided informed consent in accordance with local Institutional Review Board requirements 
and the Declaration of Helsinki.  
 The study included also 2 validation cohort. The Binet A validation cohort was of a 
multicenter cohort of 402 patients from 4 different institutions (Università Vita-Salute San 
Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; University of Modena and Reggio 
Emilia, Modena, Italy; University of Perugia, Perugia, Italy; Sapienza University of Rome, 
Rome, Italy). The Rai 0 validation cohort was of a multicenter cohort of 395 patients 
previously described elsewhere (Cohen et al., 2020).  
 
3.2 Fluorescence In Situ Hybridization (FISH)   
            FISH procedure starts from sample preparation, in which red cells contained in 
500µL of PB are lysed in hypotonic solution and, then the white cells in interphase are fixed 
using a fixative solution composed of acetic acid and methanol. The hybridization step allows 
the binding of specific probes to the region of interest and the observation of the nucleus 
using a fluorescence microscope.  
           For this project, the labelled probes used for the FISH analysis are XCE 12 probe for 
tris12 detection (MetaSystems, Altlussheim, Germany), XL DLEU/TP53 probe for del17p 
detection (Cytocell Acquarius, Cambridge, England), XL ATM/11cen locus-specific probe 
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for del11q detection (Cytocell Acquarius Cambridge, England), and XL DLEU/LAMP probe 
for del13q detection (MetaSystems Altlussheim, Germany).   
  
3.3 Resequencing gene panel  
            A targeted resequencing gene panel was designed to include the coding exons plus 
the splice sites of 10 CLL driver genes known to be implicated in CLL pathogenesis and/or 
prognosis (size of the target region: 26963 bp).   
The gene panel included the most frequently mutated genes in CLL, namely 
NOTCH1, TP53, ATM, SF3B1, MYD88, EGR2, XPO1, NFKBIE, POT1 and BIRC3 (Landau 
et al., 2015; Puente et al., 2015).  
  
3.4 Extraction of gDNA for library preparation  
             Tumor and normal gDNA were extracted by using the “salting out” protocol (Miller 
et al., 1988). PB was diluted 1:2 with physiological solution (NaCl 0.9%) and then 
centrifuged in a gradient differentiation Sigma DiagnosticTM Histopaque®-1077 Cell 
Separation Medium (Sigma-Aldrich, St. Louis, MO, USA) solution to obtain mononuclear 
white blood cells and granulocytes.   
Cells were lysed with Lysis Buffer (Tris-HCl 1M, pH 8.2, NaCl 5M, EDTA 0.5M), 
SDS 20% and digested with pronase E (20 mg/mL). Samples were incubated at 37°C 
overnight in a shaking incubator. Proteins were precipitated with 6M NaCl, and subsequently 
discarded after centrifugation at 3200 rpm for 20 minutes. DNA was isolated by precipitation 
with pure ethanol and washed three times with 75% ethanol. The excess ethanol was 
evaporated and the DNA was dissolved with TE buffer (Tris-HCl 1M, pH 8.2 and EDTA 
0.5M).   
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3.5 DNA fragmentation and quantification   
Tumor and germline gDNA were quantified using the Quant-iTTM PicoGreen double 
strand DNA (dsDN)A Assay kit (ThermoFisher Scientific, Eugene, OR, USA). PicoGreen is 
a molecule that binds selectively to double helix DNA and allows to obtain a precise estimate 
of the amount of DNA.  The fluorimetric reading was performed using the Infinite F200 
fluorometer (TECAN, Männedorf, Switzerland) using the Magellan software. The 
fluorimetric readings were obtained at a wavelength of 485 nanometer (nm) in absorption 
and 530 nm in emission. For quantification a standard curve was prepared using a DNA of 
known concentration and performing serial 1:2 scalar dilutions. Quant-iTTM PicoGreen 
dsDNA Assay kit was used at the 1:200 dilutions.   
Five hundred nanograms were sheared through sonication (Covaris M220 
focusedultrasonicator, Woburn, MA, USA) before library construction to obtain 250/300-
base pair (bp) fragments. The size of the DNA fragments was checked using the Bioanalyzer 
2100 (Agilent Technologies, St. Clara, CA, USA).  
The Bioanalyzer 2100 was used to verify size of the DNA fragments. This technology 
is based on a microfluidic plate that allows quantitative and qualitative analysis of DNA 
almost instantaneously. The High Sensitivity DNA kit was used to evaluate the DNA and 
library construction to obtain 250/300-bp fragments.  
  
3.6 CAPP-seq library preparation   
The NGS libraries for gDNA were constructed using the KAPA Library Preparation Kit  
(Kapa Biosystems, Wilmington, MA, USA). Hybrid selection was performed with the 
custom SeqCap EZ Choice Library (Roche NimbleGen, Madison, WI, USA). Multiplexed 
libraries (n = 10 per run) were sequenced using 300-bp paired-end runs on a MiSeq sequencer 
(Illumina, San Diego, CA, USA).   
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3.7 Next Generation Sequencing  
            The mutational analysis in NGS was performed using the MiSeq (Illumina) platform, 
which allows for massive high-throughput sequencing of the genomic regions of interest.   
The sequencing workflow involves the following phases: (i) generation of libraries 
containing the regions of interest; (ii) sequencing; and (iii) data analysis.  
  
i) Libraries generation  
The library preparation using the KAPA Library Preparation Kit (Kapa Biosystems) 
begins with end repair and A-tailing reaction, which produces end repaired, 5’-
phosphorylation, 3’- Atailed dsDNA fragments, followed by the adapter ligation, during 
which dsDNA adapters with 3’-dTMP overhangs are ligated to 3’-dA-tailed molecules.  
    
 ii) Next Generation Sequencing  
The MiSeq Illumina sequencer is based on sequencing by synthesis technology, in 
which DNA libraries are transferred onto a solid support called flowcell, to which they are 
linked by special adapters. On the flowcell the libraries are amplified by a method called 
bridge amplification, which generates clusters of identical DNA molecules, each derived 
from the amplification of a single molecule.   
Sequencing is based on the reversible cyclic termination method, with a by-synthesis 
approach, which includes three steps: the incorporation of the nucleotide, the detection of the 
fluorescence image and the cut.   
In the first phase of the cycle, the DNA polymerase elongates a specific primer by 
adding a nucleotide covalently bound to a fluorophore. This presents a block on the 3'-OH 
of ribose which does not allow polymerization with other nucleotides. Each nucleotide base 
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is bound to a fluorophore of a specific colour. It follows the detection step of the image that 
recognizes the specific emission wavelength of the fluorophore. Next, the cut removes both 
the fluorophore and the inhibitory group present at the 3'-OH end, allowing the beginning of 
a new cycle. Libraries were sequenced by pair-end sequencing using a 300-bp paired-end 
cycle kit. The library pool was denatured using 0.2N NaOH. An amount of 10 to 12 
picomolar (pM) denatured DNA was loaded into the MiSeq reagent cartridge, which also 
contained all the reagents necessary for the sequencing reaction.  
  
 iii) NGS data analysis 
            During the sequencing run, the integrated software for real-time primary analysis 
(RTA, Real Time Analysis, Illumina) performs image analysis and identification of the bases 
and assigns a qualitative score (Phred score) to each base for each cycle.   
Once the primary analysis is completed, the MiSeq Reporter (Illumina) software 
performs a secondary analysis on the data generated by the RTA through a series of 
procedures that include: i) de-multiplexing, in which the data of different samples sequenced 
are pulled together based on the specific sample index sequences; ii) FASTQ generation, 
which are files containing all the reads obtained from sequencing.  
 FASTQ sequencing reads were deduped by utilizing the FastUniq v1.1. Then, the deduped 
FASTQ sequencing reads were locally aligned to the hg19 version of the human genome 
assembly using the BWA v.0.6.1 software with the default setting, and sorted, indexed and 
assembled into a mpileup file using SAMtools v.1.   
For cases provided with paired normal gDNA, single nucleotide variations and indels 
were called in tumor gDNA versus normal gDNA, with the somatic function of VarScan2. 
A Z-test was used to compare the variant allele frequency vs the mean allele frequency in 
unpaired normal gDNA samples to filter out variants below the base-pair resolution 
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background frequencies across the target region. Only variants that had a significant call in 
Z-test were retained (Bonferroni adjusted p<4.685157e-7). For cases not provided with 
paired normal gDNA, single nucleotide variations and indels were called in tumor gDNA 
with the CNS function of VarScan2.   
The variants called by VarScan 2 were annotated by using the SeattleSeq Annotation  
138 tool (http://snp.gs.washington.edu/SeattleSeqAnnotation138) by using the default 
setting. Variants annotated as SNPs according to dbSNP 138 (with the exception of TP53 
variants that were manually curated and scored as SNPs according to the International 
Agency for Research on Cancer TP53 database; http://p53.iarc.fr), intronic variants mapping 
>2 bp before the start or after the end of coding exons, and synonymous variants were then 
filtered out.   
Among the remaining variants, only protein truncating variants (i.e. indels, stop 
codons and splice site mutations), as well as missense variants not included in the dbSNP 
138 and annotated as somatic in the COSMIC v85 database 
(https://cancer.sanger.ac.uk/cosmic), were retained.   
  
2.8 Statistical analysis  
Medical statistical analysis was performed using SPSS version 24.0. (Chicago, IL, 
USA). Primary endpoint of survival analysis was time to first treatment (TTFT) defined as 
the time interval between the date of CLL diagnosis and the date of first CLL treatment. Time 
to event outcomes were estimated using the Kaplan-Meir method and compared between 
groups using the Log-Rank test. A false discovery rate approach was used to account for 
multiple testing, and adjusted p-values were calculated using the Bonferroni correction. The 
adjusted association between exposure variables and TTFT was estimated by Cox regression. 
Statistical significance was defined as p value <0.05.  
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4 RESULTS 
4.1 Patient characteristics   
Among the 295 CLL cases with early stage Binet A CLL, the median age was 70.8 
years old, 136 (46.1%) patients were female and 159 (53.9%) were male, the median 
lymphocyte count was 8,500/L, the median hemoglobin level was 14.0 g/dL and the median 
platelet count was 205,000/L. The biological features of these patients were consistent with 
asymptomatic early stage CLL patients. Consistently, 71/285 (24.9%) harbored unmutated 
IGHV genes, 44/291 (15.1%) had trisomy 12, 12/291 (4.2%) had 17p deletion, 15/291 (5.2%) 
had 11q deletion and 150/291 (51.5%) had 13q deletion. All clinical and biological 
characteristics of the studied cohort are reported in Table 1.  




Female 136 (46.1%) 
Median age N=295 70.8 years 
Median lymphocyte count N=295 8,500/L 
Median hemoglobin level N=294 14.0 g/dL 




















No Trisomy 12 247 (84.9%) 
      




Table 1: Clinical data of the 295 CLL patients included in the study.  
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4.2 Mutational profile of the studied cohort  
  The mutational analysis, based on targeted resequencing of the genes recurrently 
mutated in CLL, was completed for all cases, with a coverage >2000x in >80% of the target 
region (26963 bp) in 90% of patients.   
The most frequently mutated gene was NOTCH1 in 25/295 (8.4%) patients, followed 
by TP53 in 17/295 (5.7%), ATM in 18/295 (6.1%), SF3B1 in 10/295 (3.3%), MYD88 in 12/295 
(4.06%), EGR2 in 6/295 (2.03%), XPO1 in 7/295 (2.3%), NFKBIE in 4/295 (1.3%), POT1 in 
2/295 (0.6%) and BIRC3 in 1/295 (0.3%) (Figure 2).  
In NOTCH1, the majority of mutations were frameshift (22/25, 88%) and the 
c.7541_7542delCT p. P2514fs*4 was the most frequent mutation, present in (17/25, 68%) of 
patients.  In TP53, the majority of mutations were missense (16/17, 94.1%) and all mutations 
clustered in the DNA binding domain of the protein. In ATM, the majority of mutations were 
missense (15/18, 83.3%). In SF3B1, all the mutations were missense (10/10, 100%). In 
MYD88, all the mutations were missense (12/12, 100%) and the c.794T>C p.L265P variant 
was the most frequent mutation, present in (8/12 ,66.6%) patients.  In EGR2, all mutations 
were missense (6/6, 100%) and the c.1150C>A p.H384N was the most frequent mutation, 
presented in (3/6, 50%) patients. In XPO1, all mutations were missense (7/7, 100%), 5/7 
(71.4%) affected the codon p.E571 and 2/7 (28.6%) the codon p.D624. In NFKBIE, all 
mutations were frameshift (4/4, 100%) and c.759_762delTTAC p.Y254fs*13 was the frequent 
mutation, present in (4/4, 100%) patients. In POT1, the two mutations were missense and the 
only BIRC3 mutation was frameshift (c.1281_1285delAAGGG; p.E429fs*7). 
 
4.3 Clinical impact of mutations  
 After a median follow-up of 10.4 years, 85 (28.8%) patients required treatment. In 
univariate analysis, molecular characteristics associated with a shorter TTFT were trisomy 12  
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(HR: 2.42; 95% CI 1.43-4.15; p=0.001), unmutated IGHV genes (HR: 4.51; 95% CI 2.83-7.05; 
p<0.0001) and mutations of XPO1 (HR: 8.88; 95% CI 3.77-20.95; p<0.0001), NOTCH1 (HR: 
3.02; 95% CI 1.66-5.51; p<0.001) and SF3B1 (HR: 2.65; 95% CI 1.15-6.10; p=0.022) (Table 
2). The median TTFT for umutated IGHV patients was 4.6 years, and was not reached for 
mutated IGHV patients (p>0.0001) (Figure 3A). The median TTFT for patients with trisomy 
12 was 9.4 years, compared to 21.0 years for patients without (p=0.001) (Figure 3B). The 
median TTFT for XPO1 mutated patients was 3.2 years compared to 21.0 years for wild type 
patients (p<0.0001) (Figure 3C). The median TTFT for NOTCH1 mutations was 7.1 years, 
compared to 21.0 years for wild type patients (p<0.001) (Figure 3D). The median TTFT for 
patients SF3B1 mutated patients was 4.9 years, compared to 21.0 years for wild type patients 
(p=0.022) (Figure 3E). Interestingly, neither 17p deletion nor TP53 mutations associated with 
a shorter TTFT, in line with the notion that TP53 disruption interacts with treatment but not 
with a watch & wait strategy (Figure 4). 
 By multivariate analysis including variables showing a multiplicity adjusted significant 
association with TTFT, XPO1 mutations (HR: 4.24; 95% CI 1.72-10.44; p=0.002) maintained 
an independent association with a shorter TTFT (Table 2). 
 Univariate analysis   Multivariate analysis  
Characteristics HR 95% CI P  P*   HR 95% CI P 
Umutated IGHV 4.51 2.83-7.05 < 0.0001 < 0.0001  3.43 2.08-5.67 < 0.0001 
17p deletion 1.96 0.71-5.38 0.191 > 0.999         
Trisomy 12 2.42 1.43-4.15 0.001 0.015  1.73 0.98-3.07 0.059 
NOTCH1 mutation 3.02 1.66-5.51 < 0.001 0.004  1.40 0.71-2.77 0.327 
SF3B1 mutation 2.65 1.15-6.10 0.022 0.33     
TP53 mutation 1.26 0.46-3.44 0.656 > 0.999         
XPO1 mutation 8.88 3.77-20.95 < 0.0001 < 0.0001   4.24 1.72-10.44 0.002 
 
Table 2. Univariate and multivariate analysis in terms of TTFT. P, P-value; P*, 





Figure 2. Overview on prevalence and molecular spectrum of non-synonymous somatic mutations discovered in the studied cohort.  
Heatmap representing the mutational profile of 83 Binet A CLL patients with at least one somatic non-synonymous mutations. Each column 
represents one patient, each row represents one gene. The fraction of patients with mutations in each gene is plotted on the right. The number and 
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Figure 3. Biological features associated with shorter TTFT. Kaplan-Meier estimates of 
TTFT of IGHV mutational status (A), Trisomy 12 (B), XPO1 mutations (C), NOTCH1 
mutations (D) and SF3B1 mutations (E). Cases harboring unmutated IGHV, Trisomy 12 and 
XPO1, NOTCH1 and SF3B1 mutations are represented by the red line. Mutated IGHV patients 
and wild type patients are represented by the blue line. The Log-rank statistics p values are 
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Figure 4. Clinical impact of 17p deletion and TP53 mutations in terms of TTFT. Kaplan-
Meier estimates of 17p deletions (A) and TP53 mutations (B). Cases harboring 17p deletion 
and TP53 mutations are represented by the red line. Wild type patients are represented by the 
blue line.  
 
 
4.4 Validation of XPO1 mutations as a predictor of shorter TTFT 
In order to validate the value of XPO1 mutations as a molecular predictor of shorter 
TTFT in early stage CLL patients, we collected and analyze two multicenter cohorts of early 
stage CLL patients composed of 402 Binet A and of 395 Rai 0 CLL patients, respectively. In 
the Binet A CLL cohort, XPO1 was mutated in 15 (3.7%) patients and significantly associated 
with a shorter TTFT with a median TTFT of 60.4 months compared to 138.6 months in wild 
type cases (Fig. 5A). Similar results were observed in the Rai 0 cohort in which XPO1 was 
mutated in 8 (2.0%) patients and significantly associated with a shorter TTFT with a median 
TTFT of 40.0 months compared to 169.0 months for wild type patients (Fig. 5B).  
By combining the training and the validation cohorts (N=1092 patients), patients 
carrying either XPO1 E571 (N=27) or D624 (N=3) mutations showed superimposable outcome 







Figure 5. Clinical impact of XPO1 mutations in terms of TTFT in the validation cohorts. 
Kaplan-Meier estimates of TTFT in the 1st validation cohort of 402 Binet A CLL patients (A), 
and in the 2nd validation cohort of 395 Rai 0 CLL patients (B). Cases harboring XPO1 mutations 
are represented by the red line and wild type cases are represented by the blue line. The Log-




Figure 6. Clinical impact of different XPO1 mutations in terms of TTFT. Kaplan-Meier 
estimates of TTFT according XPO1 mutation type combining the training and the validation 
cohorts. Patients with XPO1 mutation in codon E571 are represented by the red line, in codon 
D624 by the yellow line and wild type cases by the blue line. The Log-rank statistics p values 
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Through a NGS approach, we performed a targeted resequencing of the 10 most 
recurrently mutated genes in CLL (Puente et al., 2015; Landau et al., 2015) to identify new 
molecular markers that may predict early treatment requirement and may help clinicians to 
better plan the watch & wait strategy in asymptomatic early stage CLL patients.   
In a cohort of 295 CLL patients, mutations of the XPO1 gene, encoding for exportin 1 
which mediates the nuclear export of proteins and RNA, sorted out as an independent predictor 
of shorter TTFT. These initial results were validated in two independent cohorts of early stage 
CLL patients. Both in the Binet A CLL cohort as well as in the Rai 0 validation cohort, XPO1 
mutations significantly associated with a shorter TTFT. Moreover, since most of mutations, 
approximately 90%, affect the glutamic acid in position 571, polymerase chain reaction based 
methods may be used to identify XPO1 mutation in a simple and time effective manner. 
Proper nucleocytoplasmic partitioning of proteins is essential to cellular homeostasis. 
Exportin-1 (XPO1) is one of the most important human protein devoted to this role (Azmi et 
al., 2020). Different proteins that are involved in different biological processes are exported by 
XPO1, including tumor suppressor proteins such as p53 and proteins that inhibit the NF-B 
pathway, essential for CLL survival and proliferation (Taylor et al., 2020; Xu et al.. 2012). 
Furthermore, XPO1 dysregulation is associated with resistance to several standard-of-care 
therapies, including chemotherapies and targeted therapies, making it an attractive target of 
novel cancer therapies. Molecular consequences of XPO1 mutations in CLL are still lacking 
but XPO1 mutations alter the NF-B and the TP53 pathways that are essential in CLL 
pathogenesis and treatment resistance and further biological studies may decipher and identify 
novel biological and therapeutic implications.   
Approximately 70% of newly diagnosed CLL patients presents in an early stage 
according to the Binet and Rai staging systems, may never require treatment, and may have a 
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life expectancy similar to the general population (Halek et al., 2018; Binet et al., 1981; Rai et 
al., 1975). Despite the indolent behavior of CLL in the majority of cases, some patients have a 
CLL clone with a high proliferation rate that may lead to early treatment requirement due to 
progressive lymphocytosis, enlarged lymph nodes, cytopenia, and systemic symptoms (Halek 
et al., 2018). Asymptomatic early stage CLL patients, are managed with a watch and wait 
strategy, and treatment is started only in case of symptomatic disease (Halek et al., 2018). Until 
now, few clinical and molecular predictors inform on the risk of treatment requirement and the 
impact of CLL gene mutations is not completely understood (Shuai et al., 2019; Hu et al., 
2019). 
Recent studies have focused on the identification of clinical and molecular features that 
might identify early stage CLL who are at risk of early progression at the time of diagnosis. 
Such patients, if identified a priori, might benefit from clinical trials comparing early 
intervention versus observation. In this context, the combination of simple clinical features and 
molecular biomarkers, namely lymphocyte count >15,000/l, palpable lymph nodes, and 
unmutated IGHV genes, identifies three different subgroups of Binet A and treatment naïve 
CLL patients with a high risk of early treatment requirement (Condoluci et al., 2020). This risk 
model, termed IPS-E , has been validated in several independent series and is a robust tool to 
inform at the time of diagnosis about the probability that a given CLL patient in early stage 
disease progresses and needs treatment (Condoluci et al., 2020). Similarly, a second model 
devised for Rai 0 CLL patients identified 17p deletion, 11q deletion, trisomy 12, unmutated 
and white blood cell count above 32,000/L as variable associated with shorter TTFT (Cohen 
et al., 2020). Since XPO1 mutations significantly associate with a significantly shorter TTFT 
in both Binet A and Rai 0 CLL patients, the integration of these mutations into the IPS-E and 
in the Rai 0 prognostic model might improve the prediction of TTFT in early stage CLL 
patients.  
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In the present study, we have arbitrarily chosen to keep a threshold of variant allele 
frequency (VAF) above 5%. This decision, on one hand, helped us to protect against 
sequencing error or against the detection of minor subclones with little biological and clinical 
relevance. Conversely, on the other hand, our strategy did not allow us to evaluate the potential 
clinical impact of mutations with a VAF less than 5%.  
In conclusion, XPO1 mutations are an independent predictor of shorter TTFT and might 
help clinicians in a better management of the watch & wait strategy for Binet A CLL patients. 
In addition, functional studies are needed to identify the biological consequences underlying 
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